Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MaxCyte Inc. Common Stock
MXCT | US
1.23
USD0.01
0.82%
MXCT | US
Loading StockChartView...
About MaxCyte Inc. Common Stock
Sector
Healthcare
Industry
Medical Devices
Earnings date
30/06/2024
As of date
02/06/2026
Close
1.23
Open
1.20
High
1.23
Low
1.14
MaxCyte Inc. a life sciences company discovers develops and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx a static electroporation instrument for small to medium scale transfection; ExPERT STx a flow electroporation for protein production and drug development as well as expression of therapeutic targets for cell-based assays; ExPERT GTx a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies as well as to pharmaceutical and biotechnology companies for use in drug discovery and development and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville Maryland.
View LessMXCT | US
Risk
100.5
Sharpe
-0.72
Luna's Score
52/100
Recommendation
Hold
Luna says (MXCT | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
65.4%1 month
100.5%3 months
78.4%6 months
70.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.80
Debt to equity
0.08
Debt to assets
0.07
Ent. to EBITDA
-11.07
Ent. to rev.
5.72
PEG
-
Other Fundamentals
EBITDA
-41.92M
MarketCap
129.95M
MarketCap(USD)
129.95M
Div. yield
-
Op. margin
-114.76
Erngs. growth
-
Rev. growth
15.30
Ret. on equity
-15.33
Short ratio
11.41
Short perc.
3.70
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.33
Range1M
0.51
Range3M
0.64
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.73
Price X volume
1.12M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -11.07 | 46.09 | Cheaper |
| Ent. to Revenue | 5.72 | 14.34 | Cheaper |
| PE Ratio | - | 30.41 | - |
| Price to Book | 1.80 | 6.21 | Cheaper |
| Dividend Yield | - | 1.78 | - |
| Std. Deviation (3M) | 78.37 | 64.12 | Riskier |
| Debt to Equity | 0.08 | -145.53 | Expensive |
| Debt to Assets | 0.07 | 0.35 | Cheaper |
| Market Cap | 129.95M | 9.70B | Emerging |
